Posts With Tag Regeneron Pharmaceuticals

Explore Regeneron Pharmaceuticals' Q1 2025 financial performance. Key insights show strong earnings and R&D focus, but declining sales and legal risks warrant a 'Hold' recommendation.

Explore Regeneron Pharmaceuticals' 8-K report detailing significant developments on April 29, 2025. Essential insights for investors and analysts tracking REGN on NASDAQ.

Discover Regeneron Pharmaceuticals' latest 8-K report detailing crucial financial updates and stock information as of January 13, 2025. Stay informed on market impacts!